Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could help monitor T-Cell lymphoma

NCT ID NCT06362148

Knowledge-focused Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a new blood test can find tiny bits of tumor DNA in people with T-cell lymphoma. The goal is to see if this test can help doctors track how well treatment is working and watch for signs of the cancer coming back. About 50 adults with newly diagnosed or returning lymphoma will give blood samples over two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with peripheral T-cell lymphomas managed at tertiary care hospitals in Denmark.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphoma. * All primary systemic PTCL entities from the International Consensus Classification 2022. * ≥18 years of age. * Life expectancy of 3 months or longer. * ECOG performance status 0-4 at study entry (PS4 only if lymphoma-induced). * Measurable disease. * Written informed consent. Exclusion Criteria: * T-cell prolymphocytic leukemia * T-cell large granular lymphocytic leukemia * Chronic lymphoproliferative disorder of NK cells * Adult T-cell leukemia / lymphoma * Aggressive NK-cell leukemia * Primary cutaneous T-cell lymphoma such as Sézary syndrome and Mycosis fungoides. * Primary cutaneous CD30 positive T-cell lymphoproliferative disorders. * Lymphomatoid papulosis. * Primary cutaneous anaplastic large cell lymphoma. * Primary cutaneous small/medium CD4-positive T-cell lymphoproliferative disorder. * Primary cutaneous gamma-delta T-cell lymphoma. * Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder. * Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma. * History of active cancer during the past year, except basal cell carcinoma of the skin or stage 0 cervical carcinoma (in situ). * Unwillingness or inability to comply with the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NK T-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lymphoma, Extranodal NK-T-Cell mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NK T-cell lymphoma Peripheral T-cell lymphoma

Contacts and locations

Locations

  • Department of Hematology, Aarhus University Hospital

    Aarhus, Central Jutland, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.